Dianthus Therapeutics, Inc.
DNTH
Jodie situation report
Dianthus Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- Reported increases in internal and external R&D costs tied to claseprubart and DNTH212 buildout and clinical activity.
Invalidation: The isolated read changes if DNTH's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind DNTH
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ZBIOZenas BioPharma, Inc.partnerMay 5, 2026 ▾
“26 Licensing Agreements In June 2022, we executed a license agreement with Zenas BioPharma, Inc.”
WXILYFiling-linked namepartnerMar 9, 2026 ▾
“We work closely with our CDMO, WuXi Biologics, to ensure their suppliers have continuity of supply of raw and intermediate materials but cannot guarantee these efforts will always be successful.”
Depended on by
ANABAnaptysBio, Inc.competitorMar 3, 2026 ▾
“For our anti-BDCA2 program, our competitors include another anti-BDCA2 antibody, litifilimab (Biogen) in Phase 3 development for SLE and CLE, and a bispecific fusion protein targeting BDCA2 and BAFF/APRIL, DNTH212 (Dianthus Therapeutics) in Phase 1 developmen…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
DNTH is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.